Global Theranostics Market Growth, Size, Trends Analysis - By Product, By Application, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Theranostics Market Introduction and Overview

According to SPER market research, 'Global Theranostics Market Size- By Product, By Application, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Theranostics Market is predicted to reach 9.15 billion by 2034 with a CAGR of 13.85%.

Theranostics combines "therapy" and "diagnostics," integrating tests and treatments in medicine. This approach tailors patient care by considering individual factors like disease biology and genetics. Diagnostic methods identify specific biomarkers, guiding the choice of suitable therapies, which can include targeted drugs, immunotherapies, or radiation therapies, aimed at increasing effectiveness and reducing side effects.

Restraints: Theranostics products are expensive to develop, test, and approve. Manufacturing costs are also costly since production procedures are difficult and need the use of advanced technologies. Economies of scale may be difficult to achieve because the majority of theranostic products are speciality or niche goods. Furthermore, the use of these technology results in additional costs for altering healthcare facilities. Patients bear the significant costs.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Product, By Application, By End-User

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Bayer AG, Beckman Coulter, Inc, Cardinal Health, Inc, Canon Medical Systems Corporation, Curium, F. Hoffmann La Roche Ltd, GE HealthCare Technologies Inc, Koninklijke Philips N.V, Lantheus Holdings, Inc, Siemens Healthnieers AG, Thermo Fisher Scientific Inc.

Global Theranostics Market Segmentation:

By Product: Based on the Product, Global Theranostics Market is segmented as; Diagnostic Imaging, Radiopharmaceuticals, IVD/Biomarker Screening, Software, Services.

By Application: Based on the Application, Global Theranostics Market is segmented as; Prostate Cancer, Bone Metastasis, Neuroendocrine Tumors, Lymphoma, Cardiovascular diseases.

By End User: Based on the End User, Global Theranostics Market is segmented as; Hospitals, Diagnostics centers, Specialty clinics, Other end-users.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: MEDE2540

1.Introduction

1.1.Scope of the report
1.2.Market segment analysis

2.Research Methodology

2.1.Research data source
- 2.1.1.Secondary Data
- 2.1.2.Primary Data
- 2.1.3.SPERs internal database
- 2.1.4.Premium insight from KOLs
2.2.Market size estimation
- 2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

4.1.Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1.Drivers
- 4.1.2.Restraints
- 4.1.3.Opportunities
- 4.1.4.Challenges

5.Market variable and outlook

5.1.SWOT Analysis
- 5.1.1.Strengths
- 5.1.2.Weaknesses
- 5.1.3.Opportunities
- 5.1.4.Threats
5.2.PESTEL Analysis
- 5.2.1.Political Landscape
- 5.2.2.Economic Landscape
- 5.2.3.Social Landscape
- 5.2.4.Technological Landscape
- 5.2.5.Environmental Landscape
- 5.2.6.Legal Landscape
5.3.PORTER's Five Forces
- 5.3.1.Bargaining power of suppliers
- 5.3.2.Bargaining power of buyers
- 5.3.3.Threat of Substitute
- 5.3.4.Threat of new entrant
- 5.3.5.Competitive rivalry
5.4.Heat Map Analysis

6.Competitive Landscape

6.1.Global Theranostics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Theranostics Market

7.Global Theranostics Market, By Product (USD Million) 2021-2034

7.1.Diagnostic imaging
- 7.1.1.MRI
- 7.1.2.PET imaging
- 7.1.3.Nuclear imaging
- 7.1.4.CT scan
- 7.1.5.Molecular imaging
- 7.1.6.Other diagnostic imaging
7.2.Radiopharmaceuticals
- 7.2.1.Lutetium-177
- 7.2.2.Samarium-153
- 7.2.3.Radium-223
- 7.2.4.Iodine-131
- 7.2.5.Yttrium-90
- 7.2.6.Gallium-68
- 7.2.7.Fluorine-18
- 7.2.8.Other radiopharmaceuticals
7.3.IVD/Biomarker screening
- 7.3.1.Polymerase chain reaction (PCR)
- 7.3.2.Next-generation sequencing (NGS)
- 7.3.3.Fluorescence in-situ hybridization (FISH)
7.4.Software and services

8.Global Theranostics Market, By Application (USD Million) 2021-2034

8.1.Prostate cancer
8.2.Bone metastasis
8.3.Neuroendocrine tumors
8.4.Lymphoma
8.5.Cardiovascular diseases
8.6.Other applications

9.Global Theranostics Market, By End-User (USD Million) 2021-2034

9.1.Hospitals
9.2.Diagnostics centers
9.3.Specialty clinics
9.4.Other end-users

10.Global Theranostics Market, (USD Million) 2021-2034

10.1.Global Theranostics Market Size and Market Share

11.Global Theranostics Market, By Region, (USD Million) 2021-2034

11.1.Asia-Pacific
- 11.1.1.Australia
- 11.1.2.China
- 11.1.3.India
- 11.1.4.Japan
- 11.1.5.South Korea
- 11.1.6.Rest of Asia-Pacific
11.2.Europe
- 11.2.1.France
- 11.2.2.Germany
- 11.2.3.Italy
- 11.2.4.Spain
- 11.2.5.United Kingdom
- 11.2.6.Rest of Europe
11.3.Middle East and Africa
- 11.3.1.Kingdom of Saudi Arabia
- 11.3.2.United Arab Emirates
- 11.3.3.Qatar
- 11.3.4.South Africa
- 11.3.5.Egypt
- 11.3.6.Morocco
- 11.3.7.Nigeria
- 11.3.8.Rest of Middle-East and Africa
11.4.North America
- 11.4.1.Canada
- 11.4.2.Mexico
- 11.4.3.United States
11.5.Latin America
- 11.5.1.Argentina
- 11.5.2.Brazil
- 11.5.3.Rest of Latin America

12.Company Profile

12.1.Bayer AG
- 12.1.1.Company details
- 12.1.2.Financial outlook
- 12.1.3.Product summary
- 12.1.4.Recent developments
12.2.Beckman Coulter, Inc
- 12.2.1.Company details
- 12.2.2.Financial outlook
- 12.2.3.Product summary
- 12.2.4.Recent developments
12.3.Cardinal Health, Inc
- 12.3.1.Company details
- 12.3.2.Financial outlook
- 12.3.3.Product summary
- 12.3.4.Recent developments
12.4.Canon Medical Systems Corporation
- 12.4.1.Company details
- 12.4.2.Financial outlook
- 12.4.3.Product summary
- 12.4.4.Recent developments
12.5.Curium
- 12.5.1.Company details
- 12.5.2.Financial outlook
- 12.5.3.Product summary
- 12.5.4.Recent developments
12.6.F. Hoffmann La Roche Ltd
- 12.6.1.Company details
- 12.6.2.Financial outlook
- 12.6.3.Product summary
- 12.6.4.Recent developments
12.7.GE HealthCare Technologies Inc
- 12.7.1.Company details
- 12.7.2.Financial outlook
- 12.7.3.Product summary
- 12.7.4.Recent developments
12.8.Koninklijke Philips N.V
- 12.8.1.Company details
- 12.8.2.Financial outlook
- 12.8.3.Product summary
- 12.8.4.Recent developments
12.9.Siemens Healthnieers AG
- 12.9.1.Company details
- 12.9.2.Financial outlook
- 12.9.3.Product summary
- 12.9.4.Recent developments
12.10.Thermo Fisher Scientific Inc
- 12.10.1.Company details
- 12.10.2.Financial outlook
- 12.10.3.Product summary
- 12.10.4.Recent developments
12.11.Others